EP4702023A1 - Inhibitor des kristallinen prolylhydroxylasedomänenhaltigen proteins (phd) und verwendungen davon - Google Patents

Inhibitor des kristallinen prolylhydroxylasedomänenhaltigen proteins (phd) und verwendungen davon

Info

Publication number
EP4702023A1
EP4702023A1 EP24796253.3A EP24796253A EP4702023A1 EP 4702023 A1 EP4702023 A1 EP 4702023A1 EP 24796253 A EP24796253 A EP 24796253A EP 4702023 A1 EP4702023 A1 EP 4702023A1
Authority
EP
European Patent Office
Prior art keywords
compound
xrpd
pattern
freebase
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24796253.3A
Other languages
English (en)
French (fr)
Inventor
Yushu YIN
Jianyu Xu
Xing LIANG
Xiao DING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InSilico Medicine IP Ltd
Original Assignee
InSilico Medicine IP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InSilico Medicine IP Ltd filed Critical InSilico Medicine IP Ltd
Publication of EP4702023A1 publication Critical patent/EP4702023A1/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35Naphthalene sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24796253.3A 2023-04-28 2024-04-26 Inhibitor des kristallinen prolylhydroxylasedomänenhaltigen proteins (phd) und verwendungen davon Pending EP4702023A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023091755 2023-04-28
PCT/CN2024/090097 WO2024222881A1 (en) 2023-04-28 2024-04-26 Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
EP4702023A1 true EP4702023A1 (de) 2026-03-04

Family

ID=93255643

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24796253.3A Pending EP4702023A1 (de) 2023-04-28 2024-04-26 Inhibitor des kristallinen prolylhydroxylasedomänenhaltigen proteins (phd) und verwendungen davon

Country Status (5)

Country Link
EP (1) EP4702023A1 (de)
KR (1) KR20250174914A (de)
CN (1) CN121127469A (de)
AU (1) AU2024260720A1 (de)
WO (1) WO2024222881A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134660A1 (en) * 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
WO2018218042A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
TW201920108A (zh) * 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
KR20240095274A (ko) * 2021-10-28 2024-06-25 인실리코 메디신 아이피 리미티드 프롤릴 히드록실라제 도메인-함유 단백질 (phd) 억제제 및 그의 용도

Also Published As

Publication number Publication date
KR20250174914A (ko) 2025-12-15
AU2024260720A1 (en) 2025-10-30
WO2024222881A1 (en) 2024-10-31
CN121127469A (zh) 2025-12-12

Similar Documents

Publication Publication Date Title
EP4339194A1 (de) Säureadditionssalz eines gesteinsinhibitors sowie kristallform, zusammensetzung und pharmazeutische verwendung davon
US8343984B2 (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
CN116322678A (zh) Jak抑制剂的盐型、晶型及其制备方法和应用
JP2025148406A (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
TW202421139A (zh) 一種含氮雜環類化合物的可藥用鹽、晶型及製備方法
CN113045582A (zh) Parp-1/pi3k双靶点抑制剂或其药学上可接受的盐及其制备方法与用途
JP2026004551A (ja) イミダゾリノン誘導体の結晶形
US20250074908A1 (en) Salt of rock inhibitor, crystal form of salt, composition, and pharmaceutical use
CN117486874A (zh) 苯并杂芳环类化合物、其药物组合物及其应用
WO2024222881A1 (en) Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
CN120917029A (zh) 结晶形式
WO2024222893A1 (en) Crystalline prolyl hydroxylase domain-containing protein (phd) inhibitor and uses thereof
JP2026513705A (ja) 結晶性プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤及びその使用
WO2021073494A1 (en) The salts of a compound and the crystalline forms thereof
WO2025167975A1 (en) Crystalline cyclin-dependent kinase (cdk) 12 and/or cdk13 inhibitor and uses thereof
WO2025209524A1 (en) Crystalline tead inhibitor and uses thereof
EP4660196A1 (de) Kristallform einer verbindung, herstellungsverfahren dafür und verwendung davon
WO2023274310A1 (zh) 嘌呤衍生物的晶型及其药物组合物
WO2026046267A1 (zh) 二氢噻吩并嘧啶衍生物的结晶形式及其用途
TW202444361A (zh) 雜環化合物的晶型、其鹽、其鹽的晶型及應用
WO2023174300A1 (zh) Btk抑制剂的晶型及其酸式盐和其酸式盐的晶型
TW202404610A (zh) 一種硼酸酯衍生物的結晶、其製備方法及用途
CN115232124A (zh) 一种atx抑制剂的结晶形式及其制备方法
BR112019024892B1 (pt) Inibidores da proteína quinase

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR